| Recent years, government has executed GMP and GSP attestation management on pharmacy enterprises according to WTO, spread medicine bid, consummated medical ensuring system , strengthened medicine price management. All these make profit of pharmacy enterprise decreased but high operation cost. Many enterprises fall into hot water. Under this circumstance, keeping continuous innovation of product is a effective way to improve competence. Developing native brand of Chinese traditional medicine is one of necessary choices to carry on Shengtai strategy.This dissertation introduces development actuality, development strategy, R&D plan, products of Shengtai Company first. Then, project development background, including demand of native medical market, policy environment, environment variety of Chinese traditional medical, compete of medical market and necessity of project development, is described. It also clarifies execution and actuality of Jinsen Naotai such as project source, feasibility analysis, project development target and plan, project organization.Based on description to Jinsen Naotai project, the dissertation analyzes the problems during project selection, feasibility, project cooperation partners, risk management, organization management, plan and control, project communication. The conclusions are absence of project management experience during project management and industrialization, lack of scientific management of project selection and establishment, short of acquisition to project adventure and without good risk management system, devoid of specialize project team, un-employ project manager, poor education and research experience, un-build performance assessment and inspiration system , limitation of project communication. The problems above mentioned leads to delay the total period of project development. Based on the analysis, according to the scientific theory of project management, the dissertation puts forward to improvement measures and schemes of problems. These suggestions should be advisable and directed to nt follow-up process and other pharmacy enterprises. |